Aurobindo Pharma Q3 Results
- BSE: 524804
- NSE: AUROPHARMA
- ISIN: INE406A01037
- Sector: Major Drugs
BSE
1,452.85
6.70 (0.46%)
6.70 (0.46%)Volume27.39 K
Updated: Wed 10 Jun, 2026 | 15:29:17
NSE
1,453.604.60 (0.32%)
4.60 (0.32%)Volume1.12 M
Updated: Wed 10 Jun, 2026 | 15:31:20
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Quarter ended Dec 25
Note: Comparison is on QoQ basis
Quarterly - Aurobindo Pharma Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 7,402.62 | 6,612.21 | 5.20% | 6,173.74 | 9.36% |
| Depreciation/ Amortization | 464.73 | 382.28 | 8.28% | 423.27 | 11.04% |
| Operating Income | 1,243.28 | 1,183.86 | -0.45% | 1,178.04 | 2.81% |
| Net Income | 910.29 | 817.38 | 7.29% | 936.29 | 7.62% |
| Other Operating Expenses Total | 2,081.29 | 1,910.18 | 4.51% | 1,610.22 | 9.33% |
| Net Income Before Taxes | 1,338.52 | 1,207.46 | 4.91% | 1,262.42 | 11.56% |
| Total Revenue | 8,645.90 | 7,796.07 | 4.35% | 7,351.78 | 8.36% |
| Selling/ General/ Admin Expenses Total | 1,310.06 | 1,109.48 | 2.56% | 989.68 | 15.78% |
| Diluted Normalized EPS | 16.43 | 14.00 | 12.49% | 16.04 | 12.87% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.